Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Tango Therapeutics Inc (TNGX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: TNGX (3-star) is a STRONG-BUY. BUY since 26 days. Profits (165.08%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
8 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $10.43
Year Target Price $10.43
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 245.46% | Avg. Invested days 33 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 543.05M USD | Price to earnings Ratio - | 1Y Target Price 10.43 |
Price to earnings Ratio - | 1Y Target Price 10.43 | ||
Volume (30-day avg) - | Beta 1.24 | 52 Weeks Range 1.03 - 12.02 | Updated Date 06/29/2025 |
52 Weeks Range 1.03 - 12.02 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -788.76% |
Management Effectiveness
Return on Assets (TTM) -26.79% | Return on Equity (TTM) -61.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 363276891 | Price to Sales(TTM) 13.25 |
Enterprise Value 363276891 | Price to Sales(TTM) 13.25 | ||
Enterprise Value to Revenue 8.86 | Enterprise Value to EBITDA -0.91 | Shares Outstanding 108394000 | Shares Floating 39979029 |
Shares Outstanding 108394000 | Shares Floating 39979029 | ||
Percent Insiders 12.59 | Percent Institutions 97.75 |
Analyst Ratings
Rating 4.75 | Target Price 10.43 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Tango Therapeutics Inc
Company Overview
History and Background
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing novel cancer therapies that exploit synthetic lethality. Founded in 2017, Tango uses its functional genomics target discovery platform, known as FACT, to identify drug targets and advance a pipeline of precision medicine therapies. The company went public in 2021.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and validating novel cancer drug targets using synthetic lethality principles.
- FACT Platform: The FACT platform is a functional genomics based target discovery platform. This platform provides the framework for discovering and validating novel drug targets for cancer treatment. The platform allows for identifying new therapies by leveraging the concept of synthetic lethality, which identifies genes that are essential for cancer cell survival but not for normal cells.
- Clinical Trials: Advancing identified drug candidates through preclinical and clinical development stages, aiming to bring new therapies to patients.
Leadership and Structure
Barbara Weber, MD, is the President and Chief Executive Officer. The organizational structure includes research, development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- TNG908: TNG908 is a MTA-cooperative PRMT5 inhibitor targeting MTAP-deleted cancers. The drug is currently in Phase 1/2 clinical trials. Tango faces competition from other companies developing PRMT5 inhibitors.
- TNG462: TNG462 is an LSD1 inhibitor for the treatment of cancers with EZH2 mutations. The drug is currently in Phase 1 clinical trials. Competitors include other companies developing LSD1 inhibitors.
Market Dynamics
Industry Overview
The oncology drug development market is highly competitive and rapidly evolving, driven by advancements in genomics, precision medicine, and immunotherapy. Significant unmet needs remain for novel therapies to treat a wide range of cancers.
Positioning
Tango Therapeutics positions itself as a leader in synthetic lethality-based drug discovery. Its FACT platform and focus on precision medicine aim to provide a competitive advantage.
Total Addressable Market (TAM)
The total addressable market for cancer therapies is estimated to be hundreds of billions of dollars annually. Tango Therapeutics is positioned to address specific subsets of this market with its precision medicine approach.
Upturn SWOT Analysis
Strengths
- Proprietary FACT platform for target discovery
- Focus on synthetic lethality in cancer
- Strong management team with expertise in oncology drug development
- Early-stage pipeline with multiple promising drug candidates
Weaknesses
- Early-stage development risks
- Reliance on FACT platform for success
- Limited clinical data to date
- Cash burn rate associated with drug development
Opportunities
- Expanding pipeline with new drug candidates
- Partnering with larger pharmaceutical companies
- Advancing lead programs into later-stage clinical trials
- Addressing unmet needs in specific cancer subtypes
Threats
- Clinical trial failures
- Competition from other oncology drug developers
- Regulatory hurdles and approval delays
- Economic downturn impacting funding availability
Competitors and Market Share
Key Competitors
- MRTX
- ARRY
- CRIS
Competitive Landscape
Tango's synthetic lethality approach differentiates it from many competitors. However, large pharmaceutical companies and other biotechnology firms are also actively pursuing oncology drug development.
Growth Trajectory and Initiatives
Historical Growth: Tango Therapeutics' historical growth is characterized by the development of its drug discovery platform and advancing its pipeline of drug candidates. As a young company, revenue generation is nascent.
Future Projections: Future growth depends on the successful advancement of its pipeline, potential partnerships, and regulatory approvals. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include advancing TNG908 and TNG462 into clinical trials and expanding the FACT platform.
Summary
Tango Therapeutics is a biotechnology company focused on discovering and developing novel cancer therapies using its proprietary FACT platform and a synthetic lethality-based approach. The company has promising early-stage drug candidates and a strong management team, but it also faces challenges associated with drug development, including clinical trial risks and competition. Future success will depend on advancing its pipeline, securing partnerships, and obtaining regulatory approvals. The company's financial health and cash burn rate need close monitoring.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tango Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-09-03 | President, CEO & Director Dr. Barbara L. Weber M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 155 | Website https://www.tangotx.com |
Full time employees 155 | Website https://www.tangotx.com | ||
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.